An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinoma

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.
   PubMed Web of Science ®Google Scholar
• Srigley JR, Delahunt B, Eble JN, et al. ISUP renal tumor panel. The international society of urological pathology (ISUP) Vancouver classification of renal neoplasia. American Journal of Surgical Pathology. 2013;37(10):1469–1489.
   PubMed Web of Science ®Google Scholar
• Moch H, Cubilla AL, Humphrey PA, et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours. Eur Urol. 2016;70(1):93–105.
   PubMed Web of Science ®Google Scholar
• Aeppli S, Schmaus M, Eisen T, et al. First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts. ESMO Open. 2021;6(1):100030.
   PubMed Web of Science ®Google Scholar
• Lyseng-Williamson KA. Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use. Drugs & Therapy Perspectives. 2018;34(10):457–465.
   PubMedGoogle Scholar
• Hirsch L, Flippot R, Escudier B, et al. Immunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell Carcinoma. Drugs. 2020;80(12):1169–1181.
   PubMed Web of Science ®Google Scholar
• Grüllich C. Cabozantinib: multi-kinase Inhibitor of MET, AXL, RET, and VEGFR2. Recent Results Cancer Res. 2018;211:67–75.
   PubMedGoogle Scholar
• Choueiri TK, Pal SK, McDermott DF, et al. A phase I study of cabozantinib (XL184) in patients with renal cell cancer. Ann Oncol. 2014 Aug;25(8):1603–1608.
   PubMed Web of Science ®Google Scholar
• Vaishampayan U. Cabozantinib as a novel therapy for renal cell carcinoma. Curr Oncol Rep. 2013 Apr;15(2):76–82.
   PubMed Web of Science ®Google Scholar
• Durante C, Russo D, Verrienti A, et al. XL184 (cabozantinib) for medullary thyroid carcinoma. Expert Opin Investig Drugs. 2011 Mar;20(3):407–413.
   PubMed Web of Science ®Google Scholar
• Lacy SA, Miles DR, Nguyen LT. Clinical pharmacokinetics and pharmacodynamics of cabozantinib. Clinical Pharmacokinetics. 2017 May;56(5):477–491.
   PubMed Web of Science ®Google Scholar
• Escudier B, Lougheed JC, Albiges L. Cabozantinib for the treatment of renal cell carcinoma. Expert Opinion on Pharmacotherapy. 2016 Dec;17(18):2499–2504.
   PubMed Web of Science ®Google Scholar
• Tanabe K, Wada J, Sato Y. Targeting angiogenesis and lymphangiogenesis in kidney disease. Nat Rev Nephrol. 2020;16(5):289–303.
   PubMed Web of Science ®Google Scholar
• Vaupel P, Mayer A. Tumor hypoxia: causative mechanisms, microregional heterogeneities, and the role of tissue-based hypoxia markers. Adv Exp Med Biol. 2016;923:77–86.
   PubMed Web of Science ®Google Scholar
• Terme M, Colussi O, Marcheteau E, et al. Modulation of immunity by antiangiogenic molecules in cancer. Clin Dev Immunol. 2012;2012:492920.
   PubMedGoogle Scholar
• Messai Y, Gad S, Noman MZ, et al. Renal cell carcinoma programmed death-ligand 1, a new direct target of hypoxia-inducible factor-2 alpha, is regulated by von Hippel-Lindau gene mutation status. Eur Urol. 2016;70(4):623–632.
   PubMed Web of Science ®Google Scholar
• Ciccarese C, Brunelli M, Montironi R, et al. The prospect of precision therapy for renal cell carcinoma. Cancer Treat Rev. 2016;49:37–44.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Kaelin WG Jr. Targeting the HIF2-VEGF axis in renal cell carcinoma. Nat Med. 2020;26(10):1519–1530.
   PubMed Web of Science ®Google Scholar
• Garajová I, Giovannetti E, Biasco G, et al. c-Met as a Target for Personalized Therapy. TranslOncogenomics. 2015;7(Suppl 1):13–31.
   Google Scholar
• Zhu B, Poeta ML, Costantini M, et al. The genomic and epigenomic evolutionary history of papillary renal cell carcinomas. Nat Commun. 2020;11(1):3096.
   PubMed Web of Science ®Google Scholar
• Shojaei F, Lee JH, Simmons BH, et al. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res. 2010;70(24):10090–10100.
   PubMed Web of Science ®Google Scholar
• Balan M, Mier y Teran E, Waaga-Gasser AM, et al. Novel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression. J Biol Chem. 2015;290(13):8110–8120.
   PubMed Web of Science ®Google Scholar
• Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011;10(12):2298–2308.
   PubMed Web of Science ®Google Scholar
• Abdelaziz A, Vaishampayan U. Cabozantinib for the treatment of kidney cancer. Expert Rev Anticancer Ther. 2017;17(7):577–584.
   PubMed Web of Science ®Google Scholar
• Takahashi M. The GDNF/RET signaling pathway and human diseases. Cytokine Growth Factor Rev. 2001;12(4):361–373.
   PubMed Web of Science ®Google Scholar
• Graham DK, DeRyckere D, Davies KD, et al. The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer. Nat Rev Cancer. 2014;14(12):769–785.
   PubMed Web of Science ®Google Scholar
• Lacy S, Hsu B, Miles D, et al. Metabolism and disposition of cabozantinib in healthy male volunteers and pharmacologic characterization of its major metabolites. Drug Metab Dispos. 2015 Aug;43(8):1190–1207. Epub 2015 May 26. PMID: 26015560.
   PubMed Web of Science ®Google Scholar
• Nguyen L, Holland J, Ramies D, et al. Effect of renal and hepatic impairment on the pharmacokinetics of cabozantinib. J Clin Pharmacol. 2016 Sep;56(9):1130–1140.
   PubMed Web of Science ®Google Scholar
• Nguyen L, Holland J, Mamelok R, et al. Evaluation of the effect of food and gastric pH on the single-dose pharmacokinetics of cabozantinib in healthy adult subjects. J Clin Pharmacol. 2015;55:1293–1302.
   PubMed Web of Science ®Google Scholar
• Nguyen L, Holland J, Miles D, et al. Pharmacokinetic (PK) drug interaction studies of cabozantinib: effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK. J Clin Pharmacol. 2015;55(9):1012–1023.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib versus Sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial. J Clin Oncol. 2017 Feb 20;35(6):591–597. Erratum in: J Clin Oncol. 2017 Nov 10;35(32):3736.Erratum in: J Clin Oncol. 2018 Feb 10;36(5):521.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Hessel C, Halabi S, et al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update. Eur J Cancer. Erratum in: Eur J Cancer. 2018 Nov;103:287. 2018;94:115–125.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, et al., Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 356(2): 115–124. 2007.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Escudier B, Powles T, et al., METEOR investigators. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 373(19): 1814–1823. 2015.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Powles T, Burotto M, et al., CheckMate 9ER investigators. Nivolumab plus Cabozantinib versus Sunitinib for advanced renal-cell carcinoma. N Engl J Med. 384(9): 829–841. 2021.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Choueiri TK, Powles T, et al. Nivolumab + cabozantinib (NIVO+CABO) vs. sunitinib (SUN) for advanced renal cell carcinoma (aRCC): outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate −9ER. Abstract presented at: ASCO Genitourinary Cancers Symposium; 2021 Feb 13; available online at: https://meetinglibrary.asco.org/record/195192/abstract.
   Google Scholar
• Bedke J, Albiges L, Capitanio U, et al. Updated European association of urology guidelines on renal cell carcinoma: nivolumab plus cabozantinib joins immune checkpoint inhibition combination therapies for treatment-naïve metastatic clear-cell renal cell carcinoma. Eur Urol. 2021;79(3):339–342.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Escudier B, Powles T, et al. METEOR investigators. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016 Jul;17(7):917–927.
   PubMed Web of Science ®Google Scholar
• McGregor BA, Lalani AA, Xie W, et al. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma. Eur J Cancer. 2020;135:203–210.
   PubMed Web of Science ®Google Scholar
• Massari F, Nunno VD, Mollica V, et al. Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice. Immunotherapy. 2019;11(17):1507–1521.
   PubMed Web of Science ®Google Scholar
• Santoni M, Massari F, Aurilio G, et al. Designing novel immunocombinations in metastatic renal cell carcinoma. Immunotherapy. 2020;12(17):1257–1268.
   PubMed Web of Science ®Google Scholar
• Bergerot P, Lamb P, Wang E, et al. Cabozantinib in combination with immunotherapy for advanced renal cell carcinoma and urothelial carcinoma: rationale and clinical evidence. Mol Cancer Ther. 2019;18(12):2185–2193.
   PubMed Web of Science ®Google Scholar
• Agarwal N, Vaishampayan U, Green M, et al. Phase Ib study (COSMIC-021) of cabozantinib in combination with atezolizumab: results of the dose escalation stage in patients (pts) with treatment-naive advanced renal cell carcinoma (RCC). Ann Oncol. 2018;29(suppl_8):872.
   PubMedGoogle Scholar
• Pal SK, Tsao CK, Suarez C, et al. 702O Cabozantinib (C) in combination with atezolizumab (A) as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): results from the COSMIC-021 study. Ann Oncol. 2020;31(suppl_4):S550.
   Google Scholar
• Choueiri TK, Albiges L, Powles T, et al. A phase III study (COSMIC-313) of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in patients (pts) with previously untreated advanced renal cell carcinoma (aRCC) of intermediate or poor risk. JCO Am Soc Clin Oncol. 2020;38:767.
   PubMed Web of Science ®Google Scholar
• Aggen DH, Ager CR, Obradovic AZ, et al. Blocking IL1 beta promotes tumor regression and remodeling of the myeloid compartment in a renal cell carcinoma model: multidimensional analyses. Clin Cancer Res. 2021;27(2):608–621.
   PubMed Web of Science ®Google Scholar
• Roy AM, Briggler A, Tippit D, et al. Neoadjuvant cabozantinib in renal-cell carcinoma: a brief review. Clin Genitourin Cancer. 2020;18(6):e688–e691.
   PubMed Web of Science ®Google Scholar
• McKay RR, Kroeger N, Xie W, et al. Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy. Eur Urol. 2014;65(3):577–584.
   PubMed Web of Science ®Google Scholar
• Massari F, Di Nunno V, Guida A, et al. Addition of primary metastatic site on bone, brain, and liver to imdc criteria in patients with metastatic renal cell carcinoma: a validation study. Clin Genitourin Cancer. 2021;19(1):32–40.
   PubMed Web of Science ®Google Scholar
• Di Nunno V, Mollica V, Schiavina R, et al. Improving IMDC prognostic prediction through evaluation of initial site of metastasis in patients with metastatic renal cell carcinoma. ClinGenitourinCancer. 2020;18(2):e83–e90.
   Google Scholar
• Gordon MS, Vogelzang NJ, Schoffski P, et al. Activity of cabozantinib (XL184) in soft tissue and bone: results of a phase II randomized discontinuation trial (RDT) in patients (pts) with advanced solid tumors. Abstract, ASCO Annual Meeting Proceedings 2011 May 20 (Vol. 29, No. 15_suppl, p. 3010).
   Google Scholar
• Bersanelli M, Buti S, Ghidini A, et al. A metanalysis on cabozantinib and bone metastases: true story or commercial gimmick? Anticancer Drugs. 2020;31(3):211–215.
   PubMed Web of Science ®Google Scholar
• Peverelli G, Raimondi A, Ratta R, et al. Cabozantinib in renal cell carcinoma with brain metastases: safety and efficacy in a real-world population. Clin Genitourin Cancer. 2019;17(4):291–298.
   PubMed Web of Science ®Google Scholar
• Wen PY, Drappatz J, De Groot J, et al. Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy. Neuro Oncol. 2018;20(2):249–258.
   PubMed Web of Science ®Google Scholar
• D’Angelo A, Bagby S, Di Pierro G, et al. An overview of the clinical use of cabozantinib in the treatment of advanced non-clear-cell renal cell carcinoma (NCCRCC). Crit Rev Oncol Hematol. 2020;149:102921.
   PubMed Web of Science ®Google Scholar
• Ged Y, Chen YB, Knezevic A, et al. Metastatic chromophobe renal cell carcinoma: presence or absence of sarcomatoid differentiation determines clinical course and treatment outcomes. Clin Genitourin Cancer. 2019;17(3):e678–e688.
   PubMed Web of Science ®Google Scholar
• Kroeger N, Xie W, Lee JL, et al. Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria. Cancer. 2013;119(16):2999–3006.
   PubMed Web of Science ®Google Scholar
• Campbell MT, Bilen MA, Shah AY, et al. Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: a retrospective analysis. Eur J Cancer. 2018;104:188–194.
   PubMed Web of Science ®Google Scholar
• Martínez Chanzá N, Xie W, Asim Bilen M, et al. Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. Lancet Oncol. 2019;20(4):581–590.
   PubMed Web of Science ®Google Scholar
• Prisciandaro M, Ratta R, Massari F, et al. Safety and efficacy of cabozantinib for metastatic nonclear renal cell carcinoma: real-world data from an Italian managed access program. Am J Clin Oncol. 2019;42(1):42–45.
   PubMed Web of Science ®Google Scholar
• Pal SK, Tangen C, Thompson IM Jr, et al., A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. Lancet. 397(10275): 695–703. 2021.
   PubMed Web of Science ®Google Scholar
• Anderson R, Jatoi A, Robert C, et al. Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs). Oncologist. 2009;14(3):291–302.
   PubMed Web of Science ®Google Scholar
• Belum VR, Serna-Tamayo C, Wu S, et al. Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis. ClinExpDermatol. 2016;41(1):8–15.
   Google Scholar
• Schmidinger M. Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors. EJC Suppl. 2013;11(2):172–191.
   PubMedGoogle Scholar
• Garber JR, Cobin RH, Gharib H, et al. American association of clinical endocrinologists and American thyroid association taskforce on hypothyroidism in adults. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American association of clinical endocrinologists and the American thyroid association. EndocrPract 2012;18(6):988–1028.
   Google Scholar
• Biondi B, Wartofsky L. Combination treatment with T4 and T3: toward personalized replacement therapy in hypothyroidism? J Clin Endocrinol Metab. 2012;97(7):2256–2271.
   PubMed Web of Science ®Google Scholar
• Schmidinger M, Danesi R. Management of adverse events associated with cabozantinib therapy in renal cell carcinoma. Oncologist. 2018;23(3):306–315.
   PubMed Web of Science ®Google Scholar
• Di Nunno V, Massari F, Mollica V, et al. Another one in the chamber: cabozantinib for patients with metastatic non clear cell renal cell carcinoma. Ann Transl Med. 2019;7(Suppl S3):S137.
   PubMedGoogle Scholar
• Powles T. ESMO guidelines committee. Electronic address: [email protected]. RecenteUpdate to the ESMO clinical practice guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer: renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(3):422–423.
   PubMed Web of Science ®Google Scholar
• Iacovelli R, Massari F, Albiges L, et al. Evidence and clinical relevance of tumor flare in patients who discontinue tyrosine kinase inhibitors for treatment of metastatic renal cell carcinoma. Eur Urol. 2015;68(1):154–160.
   PubMed Web of Science ®Google Scholar
• Iacovelli R, Ciccarese C, Facchini G, et al. Cabozantinib after a previous immune checkpoint inhibitor in metastatic renal cell carcinoma: a retrospective multi-institutional analysis. Target Oncol. 2020;15(4):495–501.
   PubMed Web of Science ®Google Scholar
• Rizzo A, Rosellini M, Marchetti A, et al. Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: a critical overview of recent evidence. Immunotherapy. 2021 Apr 7;13(8):685–692. Epub ahead of print. PMID: 33823678.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Motzer RJ, Rini BI, et al. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol. 2020 Aug;31(8):1030–1039. Epub 2020 Apr 25. PMID: 32339648.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Tannir NM, McDermott DF, et al., CheckMate 214 investigators. Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma. N Engl J Med. 378(14): 1277–1290. 2018.
   PubMed Web of Science ®Google Scholar
• Motzer R, Alekseev B, Rha SY, et al. CLEAR trial investigators. Lenvatinib plus Pembrolizumab or Everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384(14):1289–1300.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Banchereau R, Hamidi H, et al. Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade. Cancer Cell. 2020;38(6):803–817.e4.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, et al., CheckMate 025 investigators. Nivolumab versus Everolimus in advanced renal-cell carcinoma. N Engl J Med. 373(19): 1803–1813. 2015.
   PubMed Web of Science ®Google Scholar
• Zhou QH, Li KW, Chen X, et al. HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma. J Immunother Cancer. 2020;8(1):e000157. Erratum in: J Immunother Cancer. 2020;8(1).
   PubMed Web of Science ®Google Scholar
• Santoni M, Buti S, Conti A, et al. Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. Target Oncol. 2015;10(4):517–522.
   PubMed Web of Science ®Google Scholar
• Rizzo A, Mollica V, Santoni M, et al. Impact of clinicopathological features on survival in patients treated with first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors for renal cell carcinoma: a meta-analysis of randomized clinical trials. Eur Urol Focus. 2021;S2405-4569(21):58.
   Google Scholar
• Santoni M, Massari F, Di Nunno V, et al. Immunotherapy in renal cell carcinoma: latest evidence and clinical implications. DrugsContext. 2018;7:212528.
   Google Scholar
• Montironi R, Santoni M, Massari F, et al. Editorial: emerging immunotargets in genitourinary tumors. Current Drug Targets. 2016;17(7):748–749.
   PubMed Web of Science ®Google Scholar
• Montironi R, Santoni M, Cheng L, et al. An overview of emerging immunotargets of genitourinary tumors. Curr Drug Targets. 2016;17(7):750–756.
   PubMed Web of Science ®Google Scholar
• Meza L, Bergerot PG, Agarwal N, et al. Is there a role for novel TKI/ICI combinations in metastatic renal cell carcinoma? Definitely maybe. Ann Oncol. 2021;32(1):12–14.
   PubMed Web of Science ®Google Scholar